Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00195676 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
A Phase 3 study, sponsored by Abbott.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,469
- Enrollment target
NCT00195676 is a Phase 3 study that has completed, run by Abbott. The registered enrollment target is 1,469 participants.
The verdict
NCT00195676, a Phase 3 study, has completed, sponsored by Abbott.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,469 participants
- Enrollment target
Study Summary
The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were then withdrawn from adalimumab treatment.
Interventions
- DRUG adalimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,469 participants |
| Start Date | 2004-05 |
| Est. Completion | 2009-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00195676
The ClinicalTrials.gov registry entry for NCT00195676 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,469 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abbott, which has 181 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which adalimumab is the first listed.
NCT00195676 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00195676 about?
NCT00195676 is a clinical study titled "Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis". The two objectives of this study were to evaluate long-term efficacy and safety of adalimumab treatment in participants who had moderate to severe chronic plaque psoriasis and to evaluate the effectiveness of adalimumab retreatment in participants who had therapeutic response to adalimumab and were ...
What is the current status of trial NCT00195676?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,469 participants. The study started on 2004-05. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00195676?
The interventions under investigation include: adalimumab (DRUG).
Who is sponsoring clinical trial NCT00195676?
This trial is sponsored by Abbott, which has 181 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.